Wang Michael C, Dolan Bridget, Huang Xiaoning, Freaney Priya M, Freed Benjamin H, Vega Lourdes, Markoski Nikola, Wainright Amy, Kane Bonnie, Seegmiller Laura E, Shah Sanjiv J, Yancy Clyde W, Neeland Ian J, Ning Hongyan, Lloyd-Jones Donald M, Khan Sadiya S
Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois, USA.
JACC Adv. 2025 Jul 14;4(8):102004. doi: 10.1016/j.jacadv.2025.102004.
The 2022 American College of Cardiology/American Heart Association heart failure (HF) guidelines recommended the use of multivariable risk equations to guide HF prevention. However, this strategy has not been prospectively assessed.
The aim of the study was to determine the feasibility of risk-based prevention of HF.
The FIT-HF (Feasibility of the Implementation of Tools for Heart Failure Risk Prediction) study was a randomized controlled pilot trial. Patients with a predicted 10-year HF risk ≥5% were randomly assigned 1:1 to receive either usual care or collaborative care with a pharmacist. All participants underwent B-type natriuretic peptide (BNP) and high-sensitivity cardiac troponin I (hs-cTn) testing and echocardiography at baseline and 1-year follow-up. The primary outcome, change in BNP at 1 year, was examined using linear mixed models. Secondary outcomes included change in hs-cTn and traditional risk factor levels. Exploratory outcomes included echocardiographic measures and lifestyle measures.
Of 101 randomized participants, 82 completed 1-year follow-up and comprised the primary analytic sample. Mean (SD) age was 70.0 (7.0) years, 45% were female, 83% self-identified as White, and mean (SD) predicted 10-year risk of HF was 12.2% (8.0). Baseline mean (SD) BNP (pg/mL) was 40.2 (28.2) and 36.5 (19.6) in the intervention and control arms, respectively. Model-estimated between-arm difference (95% CI) in BNP at 1 year follow-up was -9.0 (-20.6 to 2.6, P = 0.13), and in hs-cTn was -1.8 (-3.5 to -0.2, P = 0.03), favoring the intervention. Differences in other secondary outcomes were not statistically significant.
FIT-HF demonstrates the feasibility of enrolling patients based on predicted risk for risk-based HF prevention; larger follow-up studies are needed to determine efficacy and long-term impact of specific preventive interventions. (Feasibility of the Implementation of Tools for Heart Failure Risk Prediction [FIT-HF]; NCT04684264).
2022年美国心脏病学会/美国心脏协会心力衰竭(HF)指南推荐使用多变量风险方程来指导HF预防。然而,这一策略尚未得到前瞻性评估。
本研究旨在确定基于风险的HF预防的可行性。
FIT-HF(心力衰竭风险预测工具实施的可行性)研究是一项随机对照试验。预测10年HF风险≥5%的患者按1:1随机分配,分别接受常规护理或与药剂师的协作护理。所有参与者在基线和1年随访时均接受B型利钠肽(BNP)、高敏心肌肌钙蛋白I(hs-cTn)检测和超声心动图检查。使用线性混合模型检查主要结局,即1年时BNP的变化。次要结局包括hs-cTn和传统危险因素水平的变化。探索性结局包括超声心动图测量和生活方式测量。
101名随机参与者中,82名完成了1年随访并构成主要分析样本。平均(标准差)年龄为70.0(7.0)岁,45%为女性,83%自我认定为白人,平均(标准差)预测10年HF风险为12.2%(8.0)。干预组和对照组基线时平均(标准差)BNP(pg/mL)分别为40.2(28.2)和36.5(19.6)。在1年随访时,模型估计的两组间BNP差异(95%CI)为-9.0(-20.6至2.6,P = 0.13),hs-cTn差异为-1.8(-3.5至-0.2,P = 0.03),干预组更优。其他次要结局的差异无统计学意义。
FIT-HF证明了基于预测风险招募患者进行基于风险的HF预防的可行性;需要更大规模的随访研究来确定特定预防干预措施的疗效和长期影响。(心力衰竭风险预测工具实施的可行性[FIT-HF];NCT04684264)